Introduction: Who Should Undergo Diagnostics

Gastroenteropancreatic neuroendocrine tumors, often called GEP-NETs, can be challenging to detect because they frequently don’t cause noticeable symptoms in their early stages. These tumors form in special cells called neuroendocrine cells, which are scattered throughout your digestive system and pancreas. These cells have characteristics of both nerve cells and hormone-producing cells, and when they become cancerous, they can behave in very different ways depending on where they are located^[1][3].

You should consider seeking diagnostic testing if you experience persistent symptoms that don’t improve with time. Common warning signs include ongoing heartburn, unexplained fatigue, muscle cramps, severe indigestion, chronic diarrhea, or weight loss that happens without trying. Some people notice pain in their abdomen or back, yellowing of the skin and eyes, or frequent bouts of dizziness. Others may have skin rashes or experience uncomfortable flushing of the face and neck^[2][4].

The age at which GEP-NETs are typically diagnosed is generally younger than for many other digestive system cancers, with most people receiving a diagnosis in their fifth decade of life. While these tumors are considered rare diseases, their incidence has increased dramatically over recent decades. Between 1973 and 2004, the number of reported cases rose by more than 400 percent, climbing from about 1 person per 100,000 to over 5 people per 100,000. This increase likely reflects improved detection methods and greater awareness among doctors, rather than a true rise in how often these tumors develop^[3][9].

Certain people face a higher risk and should be especially vigilant about symptoms. If anyone in your biological family has been diagnosed with multiple endocrine neoplasia type 1 (MEN1), Von Hippel-Lindau disease, or neurofibromatosis type 1, your risk increases significantly. These are inherited conditions that involve mutations in specific genes and can lead to the development of multiple tumors in various organs. Additionally, if you have conditions that affect your stomach’s ability to produce acid, such as atrophic gastritis, pernicious anemia, or Zollinger-Ellison syndrome, you should discuss screening with your healthcare provider^[3][10].

It’s also worth noting that most GEP-NETs occur sporadically, meaning they happen by chance without any clear family connection or inherited risk factor. However, because they can be part of familial syndromes in some cases, understanding your family health history can help your doctor determine whether you need more careful monitoring or earlier screening^[3].

Diagnostic Methods for Identifying GEP-NETs

Diagnosing gastroenteropancreatic neuroendocrine tumors requires a combination of different approaches because no single test can provide all the information doctors need. The diagnostic process typically begins with a thorough physical examination and a detailed discussion about your symptoms. Your healthcare provider will ask when your symptoms started, whether they’re getting worse, and if anyone in your family has certain inherited disorders that increase the risk of these tumors^[4].

Blood and Urine Tests

Laboratory testing plays a crucial role in detecting GEP-NETs, especially those that release hormones into your bloodstream. Blood tests can measure levels of various hormones and other substances that may indicate the presence of a tumor. One commonly tested marker is chromogranin A, a protein that neuroendocrine cells release. While not mandatory, measuring chromogranin A can be useful if levels are elevated at diagnosis, as this helps doctors monitor the tumor over time. Another substance sometimes measured is neuron-specific enolase (NSE), though this is not routinely required^[13].

For functional tumors, which are those that produce excess hormones, more specific blood tests are necessary. If doctors suspect an insulinoma, which produces too much insulin, they will test your fasting blood glucose along with serum insulin, pro-insulin, and C-peptide levels while you are experiencing low blood sugar. For a gastrinoma, which makes excessive gastrin and can lead to severe stomach ulcers, serum gastrin levels are measured. If a glucagonoma is suspected, serum glucagon will be tested. When a VIPoma is a possibility, doctors check for elevated levels of vasoactive intestinal peptide in your blood^[13].

Urine tests may also be performed, particularly when doctors suspect carcinoid syndrome, a condition that occurs when certain GEP-NETs release large amounts of serotonin and other substances. These tests look for breakdown products of these hormones that appear in urine samples^[3].

Imaging Studies

Visualizing the tumor and determining its location and extent is essential for planning treatment. Several imaging techniques are used to examine different parts of your digestive system and pancreas. Computed tomography (CT) scans of the abdomen and pelvis are frequently recommended. These scans use multiple X-ray images taken from different angles and combine them with computer processing to create detailed cross-sectional pictures of your internal organs. For GEP-NETs, a special technique called multiphasic CT may be used, which takes images at different times after contrast dye is injected, helping to show how blood flows through the tumor^[4][13].

Magnetic resonance imaging (MRI) is another powerful tool that uses magnetic fields and radio waves instead of radiation to create detailed images. MRI is particularly useful for examining soft tissues and can sometimes provide better detail than CT scans for certain types of tumors. Like CT scans, MRI may also be performed using contrast agents and multiple phases to improve visualization^[4][13].

For tumors in the stomach or early parts of the small intestine, doctors often use esophagogastroduodenoscopy (EGD), a procedure where a flexible tube with a camera is passed through your mouth into your esophagus, stomach, and the first part of your small intestine. This allows direct visualization of the lining of these organs and the opportunity to take tissue samples. Similarly, for tumors in the colon or rectum, colonoscopy or sigmoidoscopy may be performed, where a camera is inserted through the anus to view the large intestine^[10][13].

Endoscopic ultrasound (EUS) combines endoscopy with ultrasound technology. During this procedure, an ultrasound probe at the tip of the endoscope creates detailed images of the digestive tract wall and nearby structures. This is particularly valuable for examining pancreatic tumors and for determining how deeply a tumor has grown into tissue layers. EUS can also guide needle biopsies to obtain tissue samples from suspicious areas^[4][13].

A specialized imaging test called somatostatin receptor scintigraphy is often very helpful for GEP-NETs because many of these tumors have receptors on their surface that bind to somatostatin, a hormone that regulates various bodily functions. During this test, a small amount of radioactive material attached to a somatostatin-like substance is injected into your bloodstream. The material accumulates in tumor cells that have these receptors, and a special camera detects the radiation to create images showing where tumors are located throughout your body. This test is sometimes referred to as an Octreoscan or neuroendocrine positron emission tomography (PET) scan^[4][13].

Another type of nuclear medicine test uses a radioactive sugar called fluorodeoxyglucose. FDG-PET scans can show areas where cells are consuming large amounts of sugar, which can indicate rapidly growing tumors. This test may be particularly useful for more aggressive, high-grade GEP-NETs. However, it’s not routinely recommended for all cases and may be considered mainly when doctors are planning radical surgery or need to clarify uncertain findings from other imaging tests^[13].

Tissue Sampling and Biopsy

While imaging and blood tests provide important clues, obtaining a sample of tumor tissue is usually necessary to confirm the diagnosis and determine the tumor’s characteristics. This is done through a biopsy, where a small piece of tissue is removed and examined under a microscope by a specialist called a pathologist. The biopsy helps determine whether the growth is indeed a neuroendocrine tumor and provides information about how quickly the tumor cells are dividing, which helps predict how aggressive the tumor might be^[3][13].

Biopsies can be obtained in several ways. During endoscopy procedures like EGD or colonoscopy, small tissue samples can be taken from suspicious areas. For pancreatic tumors or tumors that have spread to the liver, doctors may perform an ultrasound-guided percutaneous biopsy, where a needle is inserted through the skin while ultrasound imaging guides it to the tumor. In some cases, tissue may be obtained during endoscopic ultrasound, where a fine needle passes through the endoscope and into the tumor^[13].

The pathologist examines the biopsy specimen to assess the tumor’s grade, which reflects how abnormal the cells look and how fast they are likely to grow. This is typically determined by counting how many cells are actively dividing (the mitotic count) or by measuring a protein called Ki-67, which indicates the percentage of cells that are in the process of dividing. Based on these findings, GEP-NETs are classified into different grades, ranging from low-grade (slow-growing) to high-grade (more aggressive)^[3][13].

Additional Diagnostic Procedures

For rectal tumors, specialized imaging techniques provide important information about the tumor’s depth and spread. Endorectal MRI uses a special probe inserted into the rectum to create detailed images of the rectal wall and surrounding tissues. This helps doctors determine whether the tumor is confined to the inner layers of the rectum or has grown deeper, which influences treatment decisions^[13].

When a gastric (stomach) neuroendocrine tumor is found, additional testing may include measuring the stomach’s acid production by checking gastric pH. This is important because some gastric NETs are related to conditions that reduce stomach acid production. A serum gastrin level is also typically measured, as elevated gastrin can drive the growth of certain types of gastric tumors^[13].

In patients with metastatic disease, where the tumor has spread to distant organs, doctors may perform imaging studies of the brain or bones if there are symptoms suggesting involvement of these areas. However, routine brain or bone scans are not recommended unless specific symptoms point to these sites. A chest CT scan may be included to check whether the tumor has spread to the lungs^[13].

Diagnostics for Clinical Trial Qualification

Clinical trials are research studies that test new treatments or combinations of treatments to find better ways to help people with GEP-NETs. If you’re considering participating in a clinical trial, you’ll need to undergo specific diagnostic tests to determine whether you meet the study’s enrollment criteria. These requirements ensure that the trial includes patients who are most likely to benefit from the experimental treatment and whose results can provide meaningful scientific information^[3].

Standard Baseline Assessments

Before enrolling in any clinical trial for GEP-NETs, you’ll typically need a comprehensive set of baseline tests that establish your current health status. This usually includes repeating many of the diagnostic tests used for initial diagnosis, even if you’ve had them before. Clinical trials need recent information, often obtained within a specific timeframe before enrollment, such as within the past four to six weeks. This ensures that the study team has an accurate picture of your disease at the start of treatment^[3].

Imaging studies are almost always required. Most trials will ask for CT scans or MRI scans of your chest, abdomen, and pelvis to document the size, location, and extent of all tumors. These baseline images serve as a reference point to measure whether the experimental treatment is working. In some trials, specialized imaging like somatostatin receptor scans may be required, particularly if the trial is testing treatments that target these receptors^[11][13].

Tumor Tissue Requirements

Many clinical trials require fresh or archived tumor tissue samples. Archived tissue refers to biopsy specimens that were collected during your initial diagnosis and stored by the pathology laboratory. These samples may be retrieved and sent to the trial’s central laboratory for additional testing. Some trials require a new biopsy to be performed specifically for the study, especially if previous biopsies are old or if the trial involves testing for specific genetic markers or molecular characteristics^[3].

The tissue is often used to confirm the diagnosis, verify the tumor grade, and assess specific features that might predict response to the experimental treatment. For example, trials testing drugs that target specific pathways in tumor cells may require testing the tumor tissue for the presence of certain proteins or genetic mutations. Studies involving treatments aimed at somatostatin receptors typically require confirmation that your tumor actually expresses these receptors on its surface^[11].

Laboratory Tests and Biomarkers

Blood tests are standard requirements for clinical trial enrollment. Beyond the basic blood counts and chemistry panels that check your overall health and organ function, trials may require measurement of specific tumor markers. For GEP-NETs, this commonly includes chromogranin A levels, which can serve as a baseline to monitor disease activity during the study. If your tumor produces specific hormones, those hormone levels will also be measured and monitored throughout the trial^[13].

Many clinical trials now include what’s called translational research, which involves collecting and analyzing blood, urine, or tissue samples to better understand how the treatment works at a molecular level. You may be asked to provide additional samples at various time points during the study. These samples might be used to look for circulating tumor cells, analyze DNA or RNA from tumor cells, or measure substances that indicate whether the treatment is affecting its intended target^[3].

Performance Status and Quality of Life Assessments

Clinical trials typically have criteria about how well participants are functioning in their daily lives. This is assessed using standardized scales that measure your performance status, which reflects your ability to care for yourself, work, and engage in normal activities. Common scales include the Eastern Cooperative Oncology Group (ECOG) scale or the Karnofsky Performance Scale. These assessments help ensure that participants are healthy enough to tolerate the experimental treatment and complete the study^[3].

Additionally, many trials include questionnaires about your symptoms and quality of life. These standardized forms ask about pain levels, fatigue, emotional well-being, and how your disease affects your daily activities. Completing these questionnaires at the beginning and throughout the trial helps researchers understand not just whether a treatment shrinks tumors, but whether it improves how patients feel and function^[3].

Exclusion Criteria Testing

Part of determining trial eligibility involves testing to confirm you don’t have conditions that would make participation unsafe or that might interfere with interpreting the study results. This might include tests to ensure your heart, liver, and kidneys are functioning well enough to handle the experimental treatment. Some trials exclude people with certain other medical conditions or those who have received specific previous treatments that could complicate the study^[3].

If you’re interested in participating in a clinical trial, discuss this with your healthcare team early in your treatment planning. They can help you understand what trials might be appropriate for your situation and what diagnostic testing would be required. Clinical trials offer access to promising new treatments before they become widely available, and participation contributes valuable information that helps improve care for future patients with GEP-NETs^[3].